53 patents
Utility
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS ALTERED AFFINITIES FOR FcyRActivating and FcyRInhibiting
18 Jan 24
The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an FcγR that activates a cellular effector (“FcγRActivating,” such as FcγRIIA or FcγRIIIA) and an FcγR that inhibits a cellular effector (“FcγInhibiting,” such as FcγRIIA) with an altered Ratio of Affinities relative to the respective binding affinities of such FcγR for the Fc region of the wild-type immunoglobulin.
Jeffrey B. Stavenhagen, Scott Koenig
Filed: 7 Sep 23
Utility
Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof
14 Dec 23
CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.
Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
Filed: 20 Mar 23
Utility
Covalent Diabodies and Uses Thereof
30 Nov 23
The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers.
Leslie S. Johnson, Ling Huang
Filed: 6 Feb 23
Utility
Compound Targeting IL-23A and Tnf-alpha and Uses Thereof
30 Nov 23
The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof.
Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
Filed: 6 Mar 23
Utility
PD-1-BINDING Molecules and Methods of Use Thereof
9 Nov 23
Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
Filed: 24 Feb 23
Utility
Methods for the Use of a PD-1 X CTLA-4 Bispecific Molecule
5 Oct 23
The present invention is directed in part to dosing regimens for administering a PD-1×CTLA-4 bispecific molecule for the treatment of cancer, and other conditions.
Bradley James SUMROW, Ezio BONVINI, Sharad SHARMA, Jon Marc WIGGINTON, Alexey Yevgenyevich BEREZHNOY
Filed: 23 Jul 21
Utility
B7-H3 Directed Antibody Drug Conjugates
31 Aug 23
The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey).
Deryk T. LOO, Ling HUANG, Leslie S. JOHNSON, Thomas SON, Juniper A. SCRIBNER, Ezio BONVINI
Filed: 6 Jan 23
Utility
Methods for the Use of a B7-H3 Antibody-drug Conjugate Alone or In Combination
20 Jul 23
The present invention is directed to dosing regimens for administering a humanized anti-B7-H3 antibody conjugated to at least one duocarmycin moiety (a “B7-H3-ADC”) for the treatment of cancer, particularly a cancer associated with expression of B7-H3.
Gerry Chester BOHAC, Deryk LOO, Juniper A. SCRIBNER, Jon Marc WIGGINTON
Filed: 10 May 21
Utility
Use of Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies
13 Jul 23
The present invention is directed to a method of treating a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including hematologic malignancies that are refractive to chemotherapeutic and/or hypomethylating agents.
Jan Kenneth Davidson, Sergio Rutella
Filed: 9 Jun 21
Utility
CD137 Binding Molecules and Uses Thereof
30 Mar 23
The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137, including antibodies, and molecules comprising epitope-binding fragments thereof The invention is further directed to multispecific binding molecules comprising one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g, a “CD137×TA Binding Molecule”).
Alexey Yevgenyevich BEREZHNOY, Gundo DIEDRICH, Paul A. MOORE, Ezio BONVINI, Kalpana SHAH
Filed: 16 Feb 21
Utility
Therapy for the Treatment of Cancer
23 Feb 23
The present invention is directed to regimens for administering one or more Antibody-Based Molecules that bind PD-1 or PD-L1, and LAG-3 (e.g, a PD-1×LAG-3 bispecific molecule) alone, or in combination with an Antibody-Based Molecule that binds a Tumor Antigen (TA) for the treatment of cancer.
Bradley James Sumrow, Ross La Motte-Mohs, Jon Marc Wigginton, Ezio Bonvini, Paul A. Moore, Scott Koenig, Xiaoyu Zhang
Filed: 18 Dec 20
Utility
Pharmaceutical Compositions of a PD-1 Antibody and Use of the Same
26 Jan 23
The present disclosure is provides pharmaceutical compositions, for storage and administration, comprising a human PD-1 (“hPD-1”) antibody (“retifanlimab”) and buffering agents.
Krishnan SAMPATHKUMAR, Yan ZHOU, Stephen James BURKE
Filed: 22 Jun 22
Utility
Bispecific Binding Molecules That Are Capable of Binding CD137 and Tumor Antigens, and Uses Thereof
22 Dec 22
The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”).
Liqin LIU, Chia-Ying Kao Lam, Gundo Diedrich, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini
Filed: 8 Aug 22
Utility
Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses Thereof
24 Nov 22
The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”).
Leslie S. Johnson, Ling Huang, Kalpana Shah, Ezio Bonvini, Paul A. Moore, Wei Chen
Filed: 8 Jun 22
Utility
Pharmaceutical Formulations of Bi-Specific Diabodies and Use of the Same
13 Oct 22
The present invention is directed to stable aqueous pharmaceutical formulations that comprise a bispecific monovalent diabody (“Diabody formulation”), and to aqueous stabilizer solutions for stabilizing and administering said diabody.
Ian Lent, Krishnan Sampathkumar
Filed: 29 May 20
Utility
ADAM9-Binding Molecules, and Methods of Use Thereof
13 Oct 22
The present invention is directed to molecules, such as monospecific antibodies and bispecific, trispecific or multispecific binding molecules, including diabodies, BITE® molecules, and antibodies that are capable of specifically binding to “Disintegrin and Metalloproteinase Domain-containing Protein 9” (“ADAM9”).
Deryk T. Loo, Juniper A. Scribner, Bhaswati Barat, Gundo Diedrich, Leslie S. Johnson, Ezio Bonvini
Filed: 17 Dec 21
Utility
Covalent Diabodies and Uses Thereof
1 Sep 22
The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers.
Leslie S. Johnson, Ling Huang
Filed: 7 Jan 22
Utility
Combination Therapy for the Treatment of Cancer
30 Jun 22
The present invention is directed to a combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 and a second molecule that that specifically binds to human PD-1 to a subject for the treatment of cancer and/or inflammation.
James Vasselli, Jon Marc Wigginton, Ezio Bonvini, Scott Koenig
Filed: 20 Sep 21
Utility
FcgammaRIIB-Specific Antibodies and Methods of Use Thereof
9 Jun 22
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA.
Leslie S. Johnson, Ling Huang, Robyn Gerena
Filed: 16 Jul 21
Utility
Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
9 Jun 22
The present invention is directed in part to pharmaceutical compositions for storage and administration comprising a) a HER2/neu antibody (“margetuximab”), b) buffering agents, and c) stabilizers, wherein said margetuximab is stable.
David Lee Farb, Yan Zhou, Krishnan Sampathkumar
Filed: 3 Dec 21